Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Harding Loevner Global Small Companies Equity. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD+9.2%
YTD+8.13%
Annualized+0.0851%
Positioning StanceCONSTRUCTIVE
Market CapSmallCap
Digest Analysis
Quick Take
"The fund underperformed in a high-beta 'junk' rally in Q3 2025, but strictly maintained its quality-focused, long-term discipline by adding high-recurring-revenue medical tech and secularly resilient IT holdings."
Executive Summary
In Q3 2025, the Harding Loevner Global Small Companies Equity composite rose 1.10% gross (0.92% net), underperforming the benchmark MSCI All Country World Small Cap Index, which rose 8.19%. The underperformance resulted from an underexposure to lower-quality high-beta stocks and gold miners that led a momentum-driven rally. The team reviews two core sectors: Health Care, where they avoid volatile small biotechs and favor diagnostic/medical equipment compounders with high recurring revenue (e.g., Sysmex, Carl Zeiss Meditec); and IT Services, where they address the cyclical and secular challenges of AI. They argue AI-induced anxieties are cyclical or transitory, citing long-term adaptability in holdings like Reply and Globant, while pointing out Besi's advanced packaging wins. Key transactions during the quarter included adding Besi, Cooper Companies, Croda, Fabrinet, MakeMyTrip, and Sysmex, while fully exiting positions in CyberArk, Robinsons Retail, and Stanley Electric.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
90%
CautiousHigh
High Conviction (90%)
High-conviction positioning: The fund underperformed in a high-beta 'junk' rally in Q3 2025, but strictly maintained its quality-focused, long-term discipline by adding high-recurring-revenue medical tech and ...
Growth Outlook
60%
BearishBullish
Neutral (60%)
Market outlook remains above average conviction: The fund underperformed in a high-beta 'junk' rally in Q3 2025, but strictly maintained its quality-focused, long-term discipline by adding high-recurring-revenue medical tech and ...
Risk Appetite
40%
DefensiveAggressive
Defensive (40%)
Risk appetite posture is moderate conviction: The fund underperformed in a high-beta 'junk' rally in Q3 2025, but strictly maintained its quality-focused, long-term discipline by adding high-recurring-revenue medical tech and ...
Capital Deployment
70%
De-riskingDeploying
Deploying (70%)
Manager actively deployed capital into high-conviction opportunities. The fund underperformed in a high-beta 'junk' rally in Q3 2025, but strictly maintained its quality-focused, long-term discipline by adding high-recurring-revenue medical tech and ...
Forward Guidance
50%
CautiousExpansionary
Neutral (50%)
Forward guidance signal: The fund underperformed in a high-beta 'junk' rally in Q3 2025, but strictly maintained its quality-focused, long-term discipline by adding high-recurring-revenue medical tech and ...
Language Signal
60%
BearishBullish
Balanced (60%)
Tone analysis indicates above average conviction language: The fund underperformed in a high-beta 'junk' rally in Q3 2025, but strictly maintained its quality-focused, long-term discipline by adding high-recurring-revenue medical tech and ...
Perceived Risk
50%
Low RiskElevated
Moderate Risk (50%)
Perceived risk level is evaluated as moderate conviction. The fund underperformed in a high-beta 'junk' rally in Q3 2025, but strictly maintained its quality-focused, long-term discipline by adding high-recurring-revenue medical tech and ...
Opportunity Density
60%
ScarceAbundant
Selective (60%)
Opportunity density index indicates above average conviction actionable entry points. The fund underperformed in a high-beta 'junk' rally in Q3 2025, but strictly maintained its quality-focused, long-term discipline by adding high-recurring-revenue medical tech and ...
Time Horizon
90%
Short-TermLong-Term
Decade+ (90%)
Investment time horizon reflects a high conviction orientation. The fund underperformed in a high-beta 'junk' rally in Q3 2025, but strictly maintained its quality-focused, long-term discipline by adding high-recurring-revenue medical tech and ...